These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26414575)

  • 1. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
    McIntyre K
    Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
    Clarke JM; Hurwitz HI; Rangwala F
    Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
    Chung C; Pherwani N
    Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
    Becze E
    ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
    Perkins SL; Cole SW
    Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
    André T; Chibaudel B
    Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
    Mitchell J; Khoukaz T; McNeal D; Brent L
    Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
    Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
    Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
    Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
    Gill S; Dowden S; Colwell B; Collins LL; Berry S
    Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.